Vito DAlessandro
Overview
Explore the profile of Vito DAlessandro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A worldwide survey on the use of animal-derived materials and reagents in scientific experimentation
Cassotta M, Bartnicka J, Pistollato F, Parvatam S, Weber T, DAlessandro V, et al.
Eng Life Sci
. 2022 Sep;
22(9):564-583.
PMID: 36093359
The use of cell and tissue-based methods in basic, applied and regulatory science has been increasing exponentially. Animal-derived components, including serum, coating materials, growth factors and antibodies are routinely used...
2.
Muscarella L, Mazza T, Fabrizio F, Sparaneo A, DAlessandro V, Tancredi A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809582
No well-established prognostic or predictive molecular markers of small-cell lung cancer (SCLC) are currently available; therefore, all patients receive standard treatment. Adequate quantities and quality of tissue samples are frequently...
3.
Rossi A, Muscarella L, Di Micco C, Carbonelli C, DAlessandro V, Notarangelo S, et al.
Expert Opin Drug Metab Toxicol
. 2017 Nov;
13(12):1281-1288.
PMID: 29095090
First- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, icotinib, and afatinib are the standard-of-care for first-line therapy of non-small-cell lung cancer (NSCLC) harboring activating...
4.
Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, et al.
J Clin Oncol
. 2017 Jan;
35(12):1281-1287.
PMID: 28135143
Purpose Considering promising results in phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide for treatment of...
5.
Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, et al.
Lung Cancer
. 2016 Sep;
100:30-37.
PMID: 27597278
Background: Chemo-radiotherapy is standard of care in the treatment of unresectable stage III NSCLC. We aimed at assessing whether the addition of concurrent taxane-chemotherapy to thoracic irradiation following chemotherapy was...
6.
Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale M, Baldini E, et al.
Clin Lung Cancer
. 2014 Dec;
16(1):67-70.
PMID: 25450879
Background: Neoangiogenesis is particularly abundant in small-cell lung cancer (SCLC) and is associated with poor prognosis. As a result of the promising nature of phase II studies, a randomized phase...
7.
8.
Muscarella L, Parrella P, DAlessandro V, la Torre A, Barbano R, Fontana A, et al.
Epigenetics
. 2011 May;
6(6):710-9.
PMID: 21610322
The KEAP1/Nrf2 pathway is a master regulator of several redox-sensitive genes implicated in resistance of tumor cells against chemotherapeutic drugs. Recent data suggest that epigenetic mechanisms may play a pivotal...
9.
Muscarella L, DAlessandro V, la Torre A, Copetti M, De Cata A, Parrella P, et al.
Cell Oncol (Dordr)
. 2011 Apr;
34(5):435-41.
PMID: 21503779
Background: Somatostatin (SS) acts as a universal endocrine off-switch, and also inhibits the growth of neuroendocrine tumours through its specific receptors (SSTRs). Somatostatin receptors are G-protein-coupled receptors, which are encoded...
10.
DAlessandro V, Greco A, Clemente C, Sperandeo M, De Cata A, Di Micco C, et al.
Tumori
. 2011 Mar;
96(6):1040-3.
PMID: 21388073
Tumor lysis syndrome has been observed in patients with bulky, treatment-sensitive tumors, in particular hematological malignancies, especially after medical treatment (chemotherapy, corticosteroids, radiation, hormonal agents, and biological response modifiers). Tumor...